• Mashup Score: 0

    In an international validation study reported in the Journal of Clinical Oncology, El Sissy et al found that the Immunoscore biopsy was capable of distinguishing risk of disease recurrence in patients with rectal cancer treated with a watch-and wait strategy. As stated by the investigators, “No biomarker capable of improving selection and monitoring of patients with rectal cancer managed by watch-and-wait strategy is currently available. Prognostic perfor mance of the Immunoscore biopsy was recently

    Tweet Tweets with this article
    • Will New Biomarker Identify Recurrence Risk in Rectal Cancer? https://t.co/ufMl5u0etv #crcsm #rectalcancer #oncology #biomarkers

  • Mashup Score: 0

    In a Korean phase II trial (KCSG HN 15-16 TRIUMPH) reported in the Journal of Clinical Oncology, Keam et al described results of a personalized biomarker-driven umbrella trial for the treatment of patients with platinum-refractory recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) using matched molecular targeted agents. In the multicenter trial, targeted next-generation sequencing was performed between October 2017 and August 2020 in 203 patients. Patients were assigned to treatment

    Tweet Tweets with this article
    • Personalized Biomarkers for Treatment of HNSCC https://t.co/glNJyjHffb #hncsm #headneckcancer #oncology #biomarkers #genomics

  • Mashup Score: 3

    Accept Cookies & Privacy Policy? This website uses cookies to ensure the best possible web experience. By continuing and using the site, you consent to the use of cookies. If you wish to disable them or to learn more about how we use cookies, please view our Cookies Policy. …

    Tweet Tweets with this article
    • Are you or a colleague doing cutting-edge work on #biomarkers, #BOS, or #ddcfDNA? Don't miss the opportunity to apply for NEW 2023 #ISHLTResearchGrants. 📅You have until the end of Sep to apply! 🔗https://t.co/Q3zlmjTWpf #ISHLT #HeartTx #LungTx https://t.co/fpvF8KEYE7